00455.HK
Tianda Pharmaceuticals Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 0.10
+0.99%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 744.9M | 322.9M | 329.9M | 532.1M | 546.7M |
| Cost of Revenue | 415.7M | 189.6M | 177.9M | 276.6M | 295.2M |
| Gross Profit | 329.2M | 133.3M | 152.0M | 255.5M | 251.5M |
| Operating Expenses | |||||
| R&D Expense | 20.1M | 8.3M | 13.3M | 13.1M | 36.1M |
| SG&A Expense | 405.8M | 179.1M | 192.9M | 271.4M | 285.5M |
| General & Admin Expense | 101.8M | 74.9M | 85.0M | 85.0M | 84.7M |
| Selling & Marketing Expense | 147.3M | 104.1M | 107.9M | 186.5M | 200.8M |
| Other Expenses | 513.0K | — | — | — | — |
| Total Operating Expenses | 426.4M | 187.4M | 206.2M | 284.6M | 321.7M |
| Cost and Expenses | 438.0M | 377.0M | (384.1M) | 563.0M | 616.8M |
| Operating Income (EBIT) | (97.2M) | (54.1M) | (54.1M) | (29.0M) | (70.1M) |
| Non-Operating | |||||
| Interest Income | (794.0K) | — | — | 3.0M | 4.3M |
| Interest Expense | 9.8M | — | 4.9M | 4.9M | 7.5M |
| Net Interest Income | (5.2M) | (3.5M) | (4.9M) | (1.9M) | (3.1M) |
| Other Non-Op Income/Expense | (12.6M) | (15.2M) | (191.0K) | 3.3M | 6.3M |
| Non-Operating Income (excl Interest) | (5.9M) | — | (4.7M) | (8.3M) | 162.00 |
| EBT (Pre-Tax Income) | (109.9M) | (69.3M) | (54.3M) | (25.7M) | (63.9M) |
| Income Tax Expense | 8.4M | 926.0K | 7.1M | (689.0K) | (4.9M) |
| Bottom Line | |||||
| Net Income | (118.2M) | (70.0M) | (61.4M) | (24.2M) | (54.6M) |
| Earnings from Cont. Ops | (118.3M) | (70.3M) | (61.4M) | (25.0M) | (59.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (118.2M) | (70.0M) | (61.4M) | (24.2M) | (54.6M) |
| Per Share | |||||
| Basic EPS | (HK$0.05) | (HK$0.03) | (HK$0.03) | (HK$0.01) | (HK$0.03) |
| Diluted EPS | (HK$0.05) | (HK$0.03) | (HK$0.03) | (HK$0.01) | (HK$0.03) |
| Revenue Per Share | HK$0.35 | HK$0.15 | HK$0.15 | HK$0.25 | HK$0.25 |
| Shares | |||||
| Basic Shares Outstanding | 2.2B | 2.2B | 2.2B | 2.2B | 2.2B |
| Diluted Shares Outstanding | 2.2B | 2.2B | 2.2B | 2.2B | 2.2B |
| Profitability Metrics | |||||
| EBITDA | (43.6M) | (24.4M) | (49.5M) | 15.7M | (19.9M) |
| D&A | 67.4M | 29.7M | 38.2M | 36.4M | 50.2M |
| EBIT | (91.4M) | (54.1M) | (49.5M) | (20.7M) | (70.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025